<DOC>
	<DOCNO>NCT00987480</DOCNO>
	<brief_summary>This genetic disease ( transmitted parent ' gene ) call Fanconi Anemia . Because genetic disease , bone marrow change failed , give rise preleukemia call myelodysplastic syndrome ( MDS ) leukemia ( acute myelogenous leukemia AML ) . Without treatment complication Fanconia anemia ( FA ) fatal . The treatment cure complication allogeneic transplant stem cell , meaning , give patient bone marrow cell healthy donor produce normal blood cell replace bone marrow sick . What give treatment FA past use combination low dose radiation whole body ( total body irradiation ) low dos chemotherapy drug ( cyclophosphamide fludarabine ) transplant . However , use radiation , later , increase chance get second cancer skin , head neck . These chance second cancer high normal patient FA . The purpose study find doctor thing chemotherapy drug use past . However physicians use another chemotherapy drug call busulfan instead radiation . The goal study get rid short term long term risk radiation . The first new part treatment replace drug radiation chemotherapy drug .</brief_summary>
	<brief_title>Hematopoietic Stem Cell Transplantation Treatment Patients With Fanconi Anemia Lacking Genotypically Identical Donor , Using Chemotherapy Only Cytoreduction With Busulfan , Cyclophosphamide Fludarabine</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must diagnosis Fanconi anemia ( confirm mitomycin C diepoxybutane [ DEB ] chromosomal breakage test approve laboratory ) . Hematologic Diagnosis Status Patients must one follow hematologic diagnosis : Severe Aplastic Anemia ( SAA ) bone marrow cellularity &lt; 25 % , Severe Isolated Single lineage Cytopenia AND least one follow feature : Platelet count &lt; 20 x 109/L platelet transfusion dependence* ANC &lt; 1000 x 109/L Hgb &lt; 8 gm/dl red cell transfusion dependence* Myelodysplastic Syndrome ( MDS ) ( Appendix 1 : MDS Classification ) MDS stage , base either one follow classification : WHO Classification Refractory anemia transfusion dependence* Any stage IPSS Classification Low risk ( score 0 ) transfusion dependence* Any risk group Score &gt; = 0.5 Acute Myelogenous Leukemia Patients acute leukemia include trial remission , refractory relapse disease . Transfusion dependence define great ONE transfusion platelet red blood cell last year prior evaluation protocol . Donors : Donor choice determine investigator center accord institutional criterion . All patient evaluate trial site eligible trial virtue disease lack HLAgenotypically match related donor capture database trial . Patients enrol protocol must one follow donor choice : HLAcompatible Unrelated volunteer donor Patients related HLAmatched donor unrelated donor either match A , B , C DRB1 ( 8/8 ) locus mismatch 1/8 locus ( A , B , C DRB1 ) ( 7/8 ) test DNA analysis ( high resolution ) , eligible entry protocol . HLAmismatched Related donor Patients related unrelated HLAcompatible donor must healthy family member least HLAhaplotype identical recipient . First degree relate donor must normal DEB test . The donor must healthy willing able receive 46 day course GCSF undergo 13 daily leukaphereses . Related Unrelated donor must medically evaluate fulfill criterion collection PBSCs per institutional guideline . Patients : Patients donor may either gender ethnic background . Patients must Karnofsky adult , Lansky pediatric performance scale status &gt; = 70 % . At time referral transplantation , patient must coexist medical problem would significantly increase risk transplant procedure . Patients must adequate physical function measure : Cardiac : asymptomatic symptomatic 1 ) LVEF rest must &gt; = 50 % must improve exercise 2 ) Shortening Fraction &gt; = 29 % Hepatic : &lt; 5 x ULN SGOT &lt; 2.0 mg/dl total serum bilirubin . Renal : serum creatinine &lt; = 1.5 mg/dl serum creatinine outside normal range , CrCl &gt; 60ml/min/1.73 m2 Pulmonary : asymptomatic symptomatic , DLCO &gt; 50 % predict ( correct hemoglobin ) Each patient must willing participate research subject must sign informed consent form . Parent legal guardian patient minor sign informed consent form . Assents obtain age appropriate . Female patient donor must pregnant breastfeeding time sign consent . Women must willing undergo pregnancy test prior transplant avoid become pregnant study . Active CNS leukemic involvement Female patient pregnant ( positive serum urine HCG ) breastfeeding . Women childbearing age must avoid become pregnant study . Active uncontrolled viral , bacterial fungal infection Patient seropositive HIVI/II ; HTLV I/II</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Anemia</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>08-031</keyword>
</DOC>